Pharmaceutical Preparations · D0 · CIK 1635088
Roivant Sciences Ltd. accelerates the development and commercialization of medicines through nimble subsidiaries
Comparable business profile · signals at a glance
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
In the 90 days to Jun 30, 2026: 1 sold $56.4M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 30, 2026 | Manchester Keith SDirector | Sell | 200,000 | $35.45 | $7.1M |
| Jun 30, 2026 | Manchester Keith SDirector | Sell | 12,380 | $35.28 | $437K |
| Jun 29, 2026 | Manchester Keith SDirector | Sell | 600,000 | $34.59 | $20.8M |
| Jun 29, 2026 | Manchester Keith SDirector | Sell | 200,000 | $34.44 | $6.9M |
| Jun 26, 2026 | Manchester Keith SDirector | Sell | 325,000 | $34.07 | $11.1M |
| Jun 26, 2026 | Manchester Keith SDirector | Sell | 300,783 | $33.92 | $10.2M |
| Mar 26, 2026 | Fitzgerald MeghanDirector | Sell | 70,000 | $27.45 | $1.9M |
| Mar 17, 2026 | Venker EricPresident & Immunovant CEO | Sell | 200,000 | $28.24 | $5.6M |
| Mar 16, 2026 | Epperly Melissa B,Director | Sell | 41,861 | $28.68 | $1.2M |
| Feb 23, 2026 | Torti FrankPresident and Vant Chair | Sell | 587,390 | $27.51 | $16.2M |
| Feb 20, 2026 | Torti FrankPresident and Vant Chair | Sell | 1,012,610 | $27.15 | $27.5M |
| Feb 19, 2026 | Torti FrankPresident and Vant Chair | Sell | 1,400,000 | $27.42 | $38.4M |
| Feb 13, 2026 | Manchester Keith SDirector | Sell | 225,000 | $26.50 | $6.0M |
| Feb 13, 2026 | Qvt Financial LpOther | Sell | 225,000 | $26.50 | $6.0M |
| Feb 13, 2026 | Gold Daniel AllenDirector | Sell | 225,000 | $26.50 | $6.0M |
| Feb 13, 2026 | Venker EricPresident & Immunovant CEO | Sell | 200,000 | $26.49 | $5.3M |
| Feb 13, 2026 | Qvt Financial LpOther | Sell | 150,784 | $26.49 | $4.0M |
| Feb 13, 2026 | Manchester Keith SDirector | Sell | 150,784 | $26.49 | $4.0M |
| Feb 13, 2026 | Gold Daniel AllenDirector | Sell | 150,784 | $26.49 | $4.0M |
| Feb 12, 2026 | Gold Daniel AllenDirector | Sell | 275,000 | $26.76 | $7.4M |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.